Reductions in the duration and nadir of neutropenia have translated into a significant decrease in bacteremia in adult recipients of allogeneic stem cell transplantation (allo-SCT) with reduced-intensity conditioning (RIC) during the first 30 days after transplantation. It remains to be determined whether RIC allo-SCT also will result in a decrease in systemic viral infections (SVls) and invasive fungal infections (IFls), which are more dependent on alterations in cellular immunity. We compared the incidence of SVls and IFls in children receiving busulfan-based RIC allo-SCTand in children receiving myeloablative conditioning (MAC) allo-SCT for various malignant and nonmalignant diseases. Allo-SCT recipients at risk for cytomegalovirus (CMV) received ganciclovir/foscarnet, and most of the patients received antifungal prophylaxis with liposomal amphotericin B until day + 100. Eighty-six patients (median age, 7.5 years; 70% with malignant disease, 30% with nonmalignant disease; 80% average risk, 20% poor risk) were evaluated. The probability of developing grade II-IVacute graft-versus-host disease (aGVHD) was 29.1 % (95% confidence interval [CI] = 16.7%-41.6%) in RIC allo-SCT versus 40.3% (95% CI=23.9%-56.6%) in MAC allo-SCT (P=.23), and that of chronic GVHD (cGVHD) was 28.9% (95% CI= 14.7%-43.0%) in RIC allo-SCT versus 28.4% (95% CI= 10.5%-46.3%) in MAC allo-SCT (P=.73). The overall probability of developing an SVI was 58%, and that of developing an IFIwas 15%.These probabilities did not differ significantly by conditioning intensity. In a multivariate Cox regression model, the following were identified as independent risk factors for invasive fungal infection: older age (hazard ratio [HR]=1.3; 95% CI=I.I-1.6; P=<.OI), poor risk status (HR=6.5; 95% CI =1.1-37.4; P=.03), and CMV-positive recipient (high vs low CMV risk group, HR=26.7; 95% CI=3.4-210.8; P=<.OI). Overall infection-related mortality was only 1.1% (1/86) for SVls and 2.3% (2/86) for IFls. Our data indicate that RIC allo-SCT does not carry a lower risk of SVls and IFls than MAC allo-SCT in pediatric recipients.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-SCT) as a treatment option for hematologic malih'11ancieshas long been based on the assumption that myeloablative (MA) doses of cytotoxic therapy are required for both disease eradication and host immunosuppression. But the last decade has seen a paradigm shift toward the curative potential of a graft-versusleukemia (GVL) or graft-versus-tumor (GVT) effect [I] . The concept behind reduced-intensity conditioning (RIC) allo-SCT is that instead of eradicating tumors through intensive/toxic chemoradiation, tumor eradication is done using the SCT donor's immune cells, relying on allogeneic GVT effects [2] . In patients with nonmalignant disease, the aim of RIC allo-SCT is to create an immunologic platform of host and donor tolerance using pre transplantation and posttransplantation immunosuppression.
Data on RIC allo-SCT in pediatric recipients are limited [3, 4] . We previously demonstrated the feasibility and safety of the RIC allo-SCT approach in children with malignant and nonmalignant diseases [5, 6] . We also demonstrated the safety of RIC allo-SCT and consolidation with gemtuzumab ozagamicin in children with average-risk acute myelogenous leukemia (AvIL) [7] .
Following myeloablative conditioning (MAC) allo-SCT, patient~experience a period of profound neutropenia, severe mucositis, and immunodeficiency that can lead to serious infectious complications that may result in significant morbidity and mortality. Theoretically, RIC allo-SCT could carry a lower risk of opportunistic infections. The potential mechanism(s) that may be responsible for this hypothetical reduced infectious morbidity following RIC allo-SCT includes shorter duration of severe neutropenia, lower grade of mucositis, enhanced immune reconstitution, decreased rate of severe acute graft-versus-host disease (aGVHD), and less use of immunosuppression compared with MAC allo-SCT [8, 9] .Junghanss et a!. [10] reported a significantly reduced risk of bacterial infection during the first 100 days posttransplantation in adult recipient~ofRIC allo-SCT. But, because of intense pretransplantation and/or posttransplantation immunosuppression, patients receiving RIC regimens actually may be at greater risk for systemic viral infections (SV1s) and invasive fungal infections (1FIs). Identified risk factors for developing SVIs after RIC allo-SCT include lymphopenia, cytomegalovims (CMV), serologic status of the donor and recipient, in vivo T cell depletion using antithymocyte globulin (ATG) oralemtuzumab, and ex vivo T cell depletion [11, 12] .
Adenovirus (ADV) and CMV are serious causes of morbidity and mortality in patients undergoing allo-SCT. CMV infection is one of the most devastating infectious complications associated with allo-SCT. CNIV reactivation occurs in 60%-80% of allo-SCT recipients who are CMV-seropositive and/or have a seropositive donor and do not receive CMV prophylaxis and/or preemptive therapy [13] . The rate of ADV infection in allo-SCT recipients is 5%-27%, and mortality ranges from 8% to 54%. The mortality rate is higher in patients with ADV pneumonia (73 %) and disseminated disease (61 %) [14] . The rate of ADV infection is 4%-6% in adult allo-SCT recipients, but as high as 47% in pediatric allo-SCT recipients [IS] .
IFI is another leading cause of infectious mortality followingallo-SCT (10%-20%) [16] . The incidence of IFIs has increased from 5.7% to 11.2% over the last decade [17] . Risk factors for developing an 11'1 include prolonged neutropenia, unrelated or mismatched donor source, and aGVHD or chronic GVHD (cGVHD) and its treatment. Adult RIC allo-SCT and MAC allo-SCT recipients have equivalent risb for aspergillosis; however, there was a trend toward increased I-year survival in RI C alIo-SCT recipients following invasive aspergillosis [18] .
There have been a few prospective ,md retrospective studies in adults regarding the incidence and outcome of SVIs and IFIs following RIC allo-SCT [10] [11] [12] . Some of tl10se studies have suggested that RIC allo-SCT is associated with increased risk of 0\1V, Epstein-Barr virus (EEV) , ADV, and IFIs [14] [15] [16] [17] [18] . Children undergoing allo-SCT may be at greater risk for primary viral infections; however, there is a paucity of data on SVIs and IFIs in children following RIC and MAC alIo-SCT. In the present study, we compared the incidence and risk factors for SVIs and IFIs following busulfan-based RIC allo-SCT versus MAC allo-SCT.
PATIENTS AND METHODS

Patients
Patients included consecutive children and adolescents who underwent busulfan (Bu)-based RIC aIlo-SCT at the Morgan Stanley Children's Hospital of New York-Presbyterian, between January 2001 and December 2007. Indications for transplantation included various malignant and nonmalignant conditions. Allogeneic stem cell sources included bone marrow (BM), peripheral blood stem cells (PBSCs), and umbilical cord blood (VCB). Poor-risk malignant patients were defined as those with chemoresistant malignant disease, in third complete remission (CR3) or greater, induction failure, progressive disease, and/or receiving a second allograft. All other patients with malignant and nonmalig'nant diseases were defined as average risk. All patients were on clinical protocols for allo-SCT approved by the Institutional Review Board at Columbia University Medical Center, and all research protocols were in compliance with the Declaration of Helsinki.
Conditioning Regimens
The conditioning regimens were protocol-driven and disease-specific. Patients with comorbid features before undergoing allo-SCT were prioritized for RIC regimens; prioritization of the remaining patients was protocol-driven and disease-specific. All patients without c0l110rbid features were offered MAC. The RIC am1 included patients who received Bu (6. (8 mglkg) . Forty-four children received rabbit ATG (MAC allo-SCT, n=21; RIC allo-SCT, n=23), and 16 children received alemtuzumab (54 mg/m2) (MAC allo-SCT, n =0; RIC allo-SCT, n= 16). Patients with acute lymphoblastic leukemia (ALL) were excluded because they were treated with a total body irradiation (TBI)-based MAC regimen.
GVHD Prophylaxis and Grading
aGVHD prophylaxis in the majority of patients (93%) consisted of tacrolimus starting at 0.03 mg/ kg/day in a continuous i.v. infusion or 0.12 mg/kg orally twice a day with dosage adjustment to maintain blood levels between 5 and 20 ng/mL, and mycophenolate mofetil (MMF) at 15-30 mg/kg every 6-12 hours either orally or i.v., as described previously [19J. Tacrolimus was started either on the first day of the conditioning regimen or day -1 pretransplantation, and M.MF was started on day + 1 posttransplantation. Tacrolimus and i\L\1F doses were tapered in patients with :S grade II aGVHD on day + 30 for malignant disease and on day + 180 for nonmalignant disease [19J. Acute GVHD and cGHVD were graded according to the Seattle criteria [20J. The 8 patients who received unrelated PBSCs also received methotrexate (MTA} 15 mg/m2 i.v. on day + 1, followed by MTX 10 mg/m2 via slow i.v. push on days +3, +6, and + 11. Six patients who did not receive tacrolimus/i\:lMF received cyclosporine (CsA) 1.5 mg/kg i.v. from day -3 to day -5, along with MTX as described above.
Infection Prophylaxis and Supportive Care
All patients were hospitalized in protective isolation, defined as a single hospital room with a high-efficiency particulate air filtration system and reverse-isolation requiring strict hand sanitization and mask use by staff for patients undergoing unrelated hematopoietic SCT. All patients received sargramostim 250~lg/m2/day i.v. from day 0 until the white blood cell count reached:::::300/mm3 for 2 days, followed by filgrastim 10~lg/kg/day i.v. or s.c. until an ,lbsolute neutrophil count (Al"JC) of:::::2500/mm3 was achieved for 3 days, as described previously [21J. Herpes simplex virus (HSV) prophylaxis consisted of acyclovir 250 mg/m2 i.v. every 8 hours from day -5 until the development of engraftment and :S grade II mucositis. Pneumocystis carinii prophylaxis consisted of trimethoprim/sulfamethoxazole until day -2 and then 3 times weekly after myeloid engraftment. Patients unable to tolerate trimethoprim/sulfamethoxazole received i.v. pentamidine prophylaxis every 2 weeks. Fungal prophylaxis consisted of Iiposoma 1amphoteri-cin B 3 mg/kg/day i.v. from day 0 through day + 100, as described previously [221. CMV prophylaxis was administered as described previously [23J. In brief, patients at risk of acquiring CMV infection (ie, a CMV-positive donor and/or recipient) after achieving an Al'JC> 750/mm3 after allo-SCT received foscarnet 90 mg/kg every other day, alternating Witll ganciclovir 5 mg/kg every other day up to day + 100.
Systemic Viral Infections
CMV Infection and CMV Disease
CMV infection was defined as isolation of the CMV virus or detection of viral nucleic acid in any body fluid or tissue specimen. CMV systemic disease was defined as the isolation of the CMV virus or detection of nucleic acid in any body fluid or tissue specimen along with evidence of end-organ disease. Low risk for CMV infection was defined as a CMV IgG-negative donor and recipient; intermediate risk, as CMV IgG-positive donor and CMV IgG-negative recipient; and high risk, as CMV IgG-positive donor and recipient or CMV IgG-positive recipient and CMV IgGnegative donor. [24J
ADV Colonization and Infection
Recovery of ADV from stool culture was defined as colonization. Patients who were culture-or polymerase chain reaction (PCR)-positive for ADV with corresponding clinical signs and symptoms were considered to have ADV infection involving tllOse site(s). Disseminated ADV disease was defined as clinical evidence of ADV infection involving 2 or more organ sites.
Other Viral Infections
BK/]C virus infection was defined as hemorrhagic cystitis with a positive urine PCR. Human herpes virus-6 (HHV-6) infection was defined as a positive PCR from blood and/or cerebrospinal fluid. Upper respiratory illness was defined as the acute onset of any rhinorrhea, sinusitis, pharyngitis, or cough with no clinical or radiologic evidence of lower respiratory tract involvement and/or hypoxia, combined with detection of the virus in upper respiratory secretions. Lower respiratory illness was defined as clinical signs and symptoms of lower respiratory involvement with radiologic evidence of new pulmonary infiltrates with or without hypoxia associated with detection of the virus in nasal washings or broncoalveolar lavage specimens [25J.
Invasive Fungal Infections
IFIs were divided into candidemia, invasive aspergillosis, and other fungi. Invasive aspergillosis was defined as possible (based on clinical signs and symptoms plus a compatible thoracic computed tomography scan or X-ray), probable (based on clinical signs and symptoms, compatible X-ray findings, plus a positive respiratolY tract culture for A.pergillu.f spp or positive g,11actomannan assay), and definite (based on positive histology for an invasive mold infection by infections. Candida infection was defined as a positive fungal blood or urine culture or evidence of infection in any organ system on radiographic evaluation or proven by biopsy.
Statistical Analysis
The "I: and t-tests were used to compare the characteristics of the 2 groups with respect to categorical and continuous variables, respectively. Continuous variables were categorized when not normally distributed. Univariate and multivariate Cox regression models were used to evaluate the association of different risk factors for posttransplantation SVIs and IFIs. The endpoint was time to diagnosis of SVIs and IFls separately. Patients were censored at relapse, death, subsequent transplantation, or end of follow-up. For patients who received more than 1 Bu-based conditioning regimen during the specified time period, only the first transplantation was evaluated. One patient whose exact date of death was unknown was censored at the date of last contact. In patients with multiple infectious outcomes posttransplantation, only the first incident that met one or both of the foregoing definitions was included in the analysis. Timedependent variables, such as GVHD, were considered potential risk factors only if they occurred before infection was diagnosed. Assumptions for proportional hazards over time were checked for each model used. Kaplan-Meier statistics and log-rank tests were used to compare time to infection and survival between groups. All reported P values are 2-sided and use a significance level of .05. All statistical calculations were performed using SAS 9.1 (SAS Institute, CalY, NC). The multivariate model controlled for recipient age, sex, diagnosis, conditioning type, stem cell source, donor type, GVI-ID, and risk.
RESULTS
Patients and Demographic Data
A total of86 patients (52 males, 34 females; median age, 7.5 years) received a Bu-based conditioning regimen during the study period. One patient who died of progressive disease on day + 1 was deemed ineligible for analysis. The RIC arm comprised 53 patients, 39 of whom (74%) underwent transplantation for a malignant condition (AML, n= 13; neuroblastoma, n=9; Hodgkin lymphoma [HL], n=8; chronic myelogenous leukemia [CML], n=4; non-Hodgkin lymphoma, n=4; and biphenotypic leukemia, n= 1) and 14 of whom (26%) underwent transplantation for a nonmalignant condition (sickle cell disease, n=7; myelodysplastic syndrome [MDS], n=2; thalassemia, n=2; severe aplastic anemia [SAA], n=2; and scleroderma, n = 1). Of the 33 patients in the MAC arm, 21 (64%) ill1derwent transplantation for a malignant condition (AML, n = 18; ALL, n = 1; undifferentiated leukemia, n= 1; and neuroblastoma, n= 1) and 12 (36%) 1m derwent transplantation for a nonmalignant condition (sickle cell disease, n=6; thalassemia, n=2; and hemophagocytic lymphohistiocytosis, n=4) (Table 1). The patients in the RIC and MAC arms had similar performance status (95.31 ± 1.6 vs 93 .8± 1.8; P=not significant).
Donor Sources
The donor sources in the RIC arm included UCB in 28, PBSCs in 20 (14 related and 6 unrelated), and BNl in 5 (4 related and 1 unrelated). In the MAC arm, the donor source was UCB in 18, PBSCs in 7 (4 related and 3 unrelated), and BM in 8 (7 related and 1 unrelated).
Engraftment
The median time to neutrophil and platelet engraftment was 17 days and 30 days, respectively in the RIC arm and 14 days and 44 days, respectively, in the MAC arm.
GVHD
The probability of developing aGVHD grade II-IV was 29. 
Infections
SVls
A total of 50 patients developed an SVI (RIC, n=29; l\1AC, n=21) a median of 37 days (range, 10-449 days) after allo-SCT. In the RIC arm, the median time to onset of SVI was 70 days (range, 10-252 days), and the infectious organisms identified included HSV (n=3), CMV (n=4), ADV (n=4), respiratory syncytial vims (RSV; n=4), polyomavims (n=6), parainfluenza (n=3), rotavirus (n=2), varicella zoster virus (VZV; n= 1), and calicivirus (n= 1). In the MAC arm, the median time to onset of SVI was 33 days (range, 11-449 days), and the following viral organisms were identified: polyomavirus (n=8), CMV (n=5), RSV (n=3), lISV (n=2), parainfluenza (n=1), HlIV-6 (n=I), rotavirus (n=I), and ADV (n=I). The overall probability of developing an Sv'I was 58%. This probability did not differ significantly by conditioning Figure  I . Kaplan-Meier probability of developing an SVI in children in the RIC arm versus those in the MAC arm. o o 300 600 900 120015001800210024002700 3000
Day
IFls
A total of 13 patients developed an 11'1 (RIC arm, n=10; MAC arm, n=3), occurring a median of 160 days (range, 8-630 days) after alIo-SCT. In the RIC arm, the median time to onset of 11'1 was 135 days (range, 8-630 days), and the species associated with infection were Candida spp (n = 7), AJ1Je"rgi//uJ" spp (n = 2), and mucor (n = 1). In the NIAC am1, the median time to onset of infection after alIo-SCT was 167 days (range, 41-260 days). Of the 3 infections in this group, 2 resulted from Candida spp and 1 frin ScedoJporium spp. Most (62%) ofthe fungal infections occurred before day + ISO. The overall probability of developing an 11'1 was 15%. This probability did not differ significantly between the RIC and MAC anns (P= .24) (Figure 2) . In univariate analysis, only age was significantly related to 11'1; children age<7.5 years appeared to have a lower risk than older children (HR=O.2; 95% CI=0.04-0.74; P=. (2) . In a multivariate Cox regression model, the following were identified as independent risk factors for 11 .Q e Q.
RIC indicates reduced intensity conditioning;
MAC, myeloablative conditioning; PBSCs, peripheral blood stem cells; BM, bone marrow; UCB, umbilical cord blood; CMV. cytomegalovirus; ANC, absolute neutrophil count; GVHD. gralt-versus-host disease.
intensity (P=.44) (Figure 1 ). In both univariate and multivariate analyses, the only statistically significant risk factor for SVI was CMV risk; subjects who were seropositive ancllor had a seropositive donor had nearly 3 times the risk of seronegative subjects with (27) 28 (33) 10 (19) 4 (12) 14 (16) 15 (28) 9 (27) 24 (28) 9 (17) (27) 13 (25) 7 (22) 20 (24) 23 (43) Figure 2 . Kaplan-Meier probability of developing an IFI in children in the RIC arm versus those in the MAC arm. in terms of overall survival (OS) (P=.4) (Fig'ure 3 
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DISCUSSION
Regimen-related mortality after MAC allo-SCT in pediatric recipients can be as high as 20%-40% [26] [27] [28] . In our experience with RIC allo-SCT in pediatric recipients, the day + 100 nonrelapse mortality (NRM) was only 1.3% [29] . This decrease in day + 100 NRM may result in part from the decreased risk of early life-threatening infections. However, these 2 different conditioning regimens (RIC and MAC) have not been compared with respect to the rates of SVIs and IF Is in pediatric allo-SCT recipients. Here, we report the incidence ofSvls and IFls in children and adolescents who received a Bu-based MAC or RIC regimen when undergoing allo-SCT. We did not include patients who received TEl-based conditioning because (1) the most common indication for a TBIbased conditioning regimen is ALL, and we have not perfonned any RIC allo-SCT for ALL, and (2) we have not used TBI as a part of the conditioning regimen for RIC allo-SCT. The literature on the use of RIC in children and adults with ALL is limited; however, a recent study by Kennedy-Nasser et a!. [30] of children with ALL who received a TBI-containing MAC regimen found a 16% incidence ofCMV reactivation (14/83), a 19% incidence of adenovirus reactivation (16/83), and a 4.8% incidence of IFls (4/83) [30] . In our study, the incidence of C,\I1V reactivation was 15%, that of adenovirus reactivation was 3%, and that ofIFI was 9.0% in the MAC arm.
We found no significant difference between pediatric RIC allo-SCT and MAC allo-SCT recipients in terms of incidence ofSVI or OS. However, the patients in the MAC arm appeared to have a significantly lower risk of IF!. These results are not surprising given that 38% of the patients in the RIC arm received an l'\1AC autologous transplantation before undergoing a RIC allo-SCT; their underlying risk of infection may have initially been greater because of previous chemotherapy. In addition, while several studies have reported a similar risk of IFI in RIC allo-SCT and MAC allo-SCT recipients, our findings are more consistent with those of Fukuda et a!., who found a trend toward a higher risk of invasive aspergillosis among nonmyeloablative (NMA) recipients [18, 31, 32] . In that study, the cumulative incidence rates of proven or probable IFI, invasive mold infections, invasive aspergillosis, and invasive candidiasis during the first year after allo-SCT with NMA conditioning were 19%, 15%, 14%, and 5%, respectively, and 39% deaths were related to a mold infection. In contrast, in our study only 2 deaths (2.3%) were related to IF!.
Despite the lower risk ofIFI in the MAC arm, the 19% overall risk of developing IFI in the RIC arm was not significantly different from the 17% incidence reported in a recent study of adult RIC allo-SCT recipients [33] . A possible reason for the higher incidence of IFls in RIC allo-SCT recipients may be secondary to the need for prolonged immunosuppression and greater risk of graft failure in RIC allo-SCT recipients. The use of alemtuzumab in immunosuppressive conditioning has been associated with delayed immune reconstitution.
Our failure to detect a significant difference in incidence of SVIs is consistent with the result~of other studies. In one matched case-controlled study of 168 adult allo-SCT recipients, the I-year incidence of CMV disease was similar in those receiving RIC and those receiving NlAC [10] . Likewise, a study by Schetelig et a!. [34] comparing aBu-based RIC allo-SCT regimen to MAC allo-SCT conditioning found no significant difference in the incidence ofCMV infection [34] .
The risk factors for SVls and IFls identified in this study, including CMV seropositivity and patient age, are similar to tllOse reported previously, with the major exception of GVHD [35, 36] . Our failure to detect an association between infection and GVHD in the present study may be from the lower incidence of GVIID in this population than has been reported previously in RIC allo-SCT recipients, and might be linked to the different GVHD prophylaxis regimens used in our cohort [37] .
One potential concern following RIC allo-SCT is the possible increase in the incidence ofEBV reactivation and Iymphoproliferative disorder, which appears to be higher in patients receiving ATG as a part of the allo-SCT conditioning regimen [38] . In our series of 86 patients, 44 received ATG (MAC arm, n=21; RIC arm, n=23) and 16 received alemtuzumab. None of the children experienced EBV reactivation, and only 1 child had EBV-negative lymphoproliferative disorder. In addition, alemtuzumab has been associated with a significant risk of CMV reactivation. Chakrabarti et a!. [39] found a 50% incidence of CMV reactivation in adult patients receiving alemtuzumab as a part of RIC allo-SCT, but a 84.8% probability of developing a CMV reactivation in those patients at intermediate and high risk for Cl\:1V [39] . Similarly in a study by Shenoy et a!. [40] of children receiving Flu, Mel, and alemtuzumab RIC, 6 of 7 CMV-positive recipients and 1 CMV-negative recipient reactivated CNlV. In our study, 36 of 53 children (68%) in the RIC arm were at intermediate or high risk for CMV infection, but only 4 of these children developed CMV reactivation, including 2 of16 children who received alemtuzumah. This low incidence of CMV reactivation in our patient population could be due to the aggressive Cl\:1V prophylaxis instituted at our center [23] . \Ve also found no significant difference in the incidence of SVIs and IFls in children who received ATG and those who received alemtuzumab.
The major limitation of this retrospective study is the small sample size of both groups. Our proportional hazards assumptions were not met, most likely due to the small sample size. ""''hen we ran these same analyses using a simple logistic regression model, CMV high-risk status was the only significant risk factor for SVI. ClVIV high-risk status, older age, and malignant condition remained significant risk factors for IFI. In addition, CMV intermediate risk, malignant disease, poor risk disease status, and IFI remained significant risk factors for mortality. These results are consistent "Tith those from the Cox regression models. Because the subjects were heterogeneous in terms of underlying disease and donor source, these preliminary analyses should be replicated in additional studies of children with more homogenous diagnoses and cell sources.
Despite these limitations, however, we believe that our central conclusions are valid. The fact that this study was conducted at a single institution ensures consistent policies and protocols in terms of prophylaxis, isolation precautions, and diagnosis of infection. Furthemore, the fact that all conditioning regimens were busulfan-based allows for grcater comparability between subjects in the 2 groups.
\\'hen assessing the risk of SVIs and lFrs in children undergoing allo-SCT, we need to consider various othcr factors beyond the conditioning regimcn. Compared with heavily pretreated patients, patients who undergo allo-SCT for nonmalignant disease (other than immunodeficiency) have a lower risk of infection following allo-SCT due to an intact immune system, absence of chemotherapy-related thymic injury, and lack of significant end organ damage. Patients with ex vivo or in vivo T cell depletion related to alemtuzumab are at risk for SVls due to delayed immune reconstitution. Donor sourcc also may have an impact on the risk of SVls and IFrs. Compared to with children undergoing allo-SCT with DCB (delayed immune reconstitution) or an unrelated donor (increased risk of GVHD), children undergoing HL\-matched sibling allo-SCT have a lower risk of GyTID and relatively faster immune reconstitution, which may lead to a decreased incidence of SVIs and lFls. One of the most critical risk factors for SVIs and lFls is GVI-ID and its treatment with steroids and other immunosuppressive therapy. In our statistical analysis, although we controlled for all of these risk factors, we were unable to demonstrate the individual impacts of these factors on the risk of SVls and lFls, likely due to the small number of subjects.
In summary, our findings indicate that in children, RlC ,llIo-SCT is not associated with a higher risk of SVIs compared with MAC allo-SCT, but might be associated with a greater incidence of IFls. Moreover, due to the availability of sophisticated monitoring and newer antibiotics and other therapeutic strategies, both SVIs and lFls are not associated with mortality in pediatric allo-SCT recipients. 
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